Evidence map›Paper›PMID 23596006›Full record

Trial reportCirculation2013

Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function.

Daniel Sürder, Robert Manka, Viviana Lo Cicero, Tiziano Moccetti, Kaspar Rufibach, Sabrina Soncin, Lucia Turchetto, Marina Radrizzani, Giuseppe Astori, Juerg Schwitter and 14 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00355186 (SWiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction), which is not on this map. Cited by 94 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 11 pooled it
28.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00355186 phase2completednot on this map

SWiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI)

TypeinterventionalSponsorUniversity of ZurichRan2006 to 2012Enrolled200ConditionsAcute Myocardial InfarctionArmsintracoronary bone marrow cells infusion
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 11 syntheses or guidelines pooled it, 194 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Stem cell treatment for acute myocardial infarction.The Cochrane database of systematic reviews · 2015
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 6 institutions in 2 countries.

Daniel SürderDepartment of Cardiology, Cardiovascular Center, University Hospital Zurich, 8091 Zürich, Switzerland.
Robert Manka
Viviana Lo Cicero
Tiziano Moccetti
Kaspar Rufibach
Sabrina Soncin
Lucia Turchetto
Marina Radrizzani
Giuseppe Astori
Juerg Schwitter
Paul Erne
Michel Zuber
Christoph Auf der Maur
Peiman Jamshidi
Oliver Gaemperli
Stephan Windecker
Aris Moschovitis
Andreas Wahl
Ines Bühler
Christophe Wyss
Sebastian Kozerke
Ulf Landmesser
Thomas F Lüscher
Roberto Corti
Biostatistical Consulting (United States) · USEpatocentro Ticino · CHUniversity Hospital of Bern · CHETH Zurich · CHInstitute for Biomedical Engineering · CHUniversity of Lucerne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntracoronary administration of autologous bone marrow-derived mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute myocardial infarction. The optimal time point of administration of BM-MNC is still uncertain and has rarely been addressed prospectively in randomized clinical trials. METHODS AND

resultsIn a multicenter study, we randomized 200 patients with large, successfully reperfused ST-segment elevation myocardial infarction in a 1:1:1 pattern into an open-labeled control and 2 BM-MNC treatment groups. In the BM-MNC groups, cells were administered either early (i.e., 5 to 7 days) or late (i.e., 3 to 4 weeks) after acute myocardial infarction. Cardiac magnetic resonance imaging was performed at baseline and after 4 months. The primary end point was the change from baseline to 4 months in global LV ejection fraction between the 2 treatment groups and the control group. The absolute change in LV ejection fraction from baseline to 4 months was -0.4±8.8% (mean±SD; P=0.74 versus baseline) in the control group, 1.8±8.4% (P=0.12 versus baseline) in the early group, and 0.8±7.6% (P=0.45 versus baseline) in the late group. The treatment effect of BM-MNC as estimated by ANCOVA was 1.25 (95% confidence interval, -1.83 to 4.32; P=0.42) for the early therapy group and 0.55 (95% confidence interval, -2.61 to 3.71; P=0.73) for the late therapy group.

conclusionsAmong patients with ST-segment elevation myocardial infarction and LV dysfunction after successful reperfusion, intracoronary infusion of BM-MNC at either 5 to 7 days or 3 to 4 weeks after acute myocardial infarction did not improve LV function at 4-month follow-up. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00355186.

Indexed as

AdultAgedBone Marrow CellsBone Marrow TransplantationFemaleFollow-Up StudiesHumansInjectionsLeukocytes, MononuclearMaleMiddle AgedMyocardial InfarctionTime FactorsTreatment OutcomeVentricular Function, Leftbone marrow–derived progenitor cellsmagnetic resonance imagingmyocardial infarctionregenerationventricular remodeling

Identifiers

PMID23596006
OpenAlexW2885361725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.